Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 464 participants.
Also called NCT02036515
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 464 participants
- Sponsor
- Registry
-
NCT02036515 -
2013-003697-26
-
- Other papers using this trial's data
- Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02036515. Randomized; double masking; primary purpose treatment. Start 2014-03-12 (actual); primary completion 2016-06-06 (actual). Results posted on 2017-07-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ertugliflozin 5 mg
- Intervention (Drug)
- Ertugliflozin 15 mg
- Intervention (Drug)
- Placebo for ertugliflozin 5 mg
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Glimepiride
- Intervention (Biological)
- Insulin
- Intervention (Drug)
- Placebo for ertugliflozin 10 mg
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct02036515- Content hash
380af673238c1d0bae14410b1667d539b585e01dde2fc5a812358ca241a591b7